

consider issuing guidance describing best practices for advancing cultural competency, language access, and sensitivity toward AAPIs in the context of the federal government's COVID-19 response, including best practices set forth by public health organizations and experts for mitigating racially discriminatory language in describing the COVID-19 pandemic. OMH is leading a Departmental response to the memorandum. In accordance with this memorandum, OMH seeks to obtain information that may become part of or inform guidance to be issued regarding best practices.

II. Definitions

For the purposes of this RFI, the following working definitions apply.

Best practices—A practice supported by evidence indicating effectiveness in advancing cultural competence, language access or sensitivity toward AAPIs in the context of the COVID-19 response, generally demonstrated through systematic review, research, evaluation or practice-based evidence. Practices could include interventions, programs, strategies, policies, procedures, processes or other activities.

COVID-19 response—Federal activities including, but not limited to:

- Data collection, utilization and reporting
- Allocation of personal protective equipment (PPE), tests, vaccines, therapeutics and other resources
- Enforcement of anti-discrimination and HIPAA requirements pertaining to availability and access to COVID-19 care and treatment
- Assistance to individuals and families experiencing disproportionate economic or health effects from COVID-19
- Training and placement of contact tracers and other workers
- Outreach related to vaccine trust and uptake, public health measures/prevention, testing, or other mitigation measure

III. Questions

• What specific best practices in the areas listed below should be included in federal guidance? Please describe the best practice(s), evidence of its effectiveness, and how it has been applied (or could be applied) to COVID-19 response activities.

- Advancing cultural competency toward AAPIs
- Advancing language access for AAPIs
- Advancing sensitivity toward AAPIs
- Mitigating racially discriminatory language against AAPIs
- Practices that apply the National Standards for Culturally and

Linguistically Appropriate Services in Health and Health Care (National CLAS Standards).

- What sources/resources should HHS use to identify additional best practices in these areas?
- What considerations should be made in the content, audiences and format for best practices guidance products, particularly to support implementation?
- How should the best practices guidance be disseminated (e.g., mechanisms, audiences)?
- Beyond issuing best practices guidance, how can HHS support implementation of the best practices?

Dated: July 12, 2021.

Juliet Bui,

Public Health Advisor, Office of Minority Health.

[FR Doc. 2021-15168 Filed 7-15-21; 8:45 am]

BILLING CODE 4150-29-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Endocrinology and Reproduction.

Date: August 5, 2021.

Time: 12:00 p.m. to 1:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Dianne Hardy, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6175, MSC 7892, Bethesda, MD 20892, 301-435-1154, dianne.hardy@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,

93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 12, 2021.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-15119 Filed 7-15-21; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Neurodevelopment, Neurodegeneration, Neuroimmunology, Infections Diseases and Brain Tumors.

Date: July 29, 2021.

Time: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Pat Manos, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5200, MSC 7846, Bethesda, MD 20892, 301-408-9866, manospa@csr.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 12, 2021.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2021-15120 Filed 7-15-21; 8:45 am]

BILLING CODE 4140-01-P